title: Risk assessment and follow-up of valvular regurgitation in Parkinson patients treated with cabergoline.
authors: Urban M
authors: UM
authors: Fietzek
authors: Lina
authors: L
authors: Riedl
authors: Andres O
authors: AO
authors: Ceballos-Baumann
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects*; D000077465:Cabergoline; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D004452:Echocardiography; D004873:Ergolines / Q000009:adverse effects*; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000453:epidemiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000453:epidemiology*; D012189:Retrospective Studies; D018570:Risk Assessment
chemical_list: D000978:Antiparkinson Agents; D004873:Ergolines; D000077465:Cabergoline